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OBJECTIVE — Perﬂuoroalkyl chemicals (PFCs) have been used worldwide in a variety of
consumer products. The effect of PFCs on glucose homeostasis is not known.
RESEARCH DESIGN AND METHODS — We examined 474 adolescents and 969
adultswithreliableserummeasuresofmetabolicsyndromeproﬁlefromtheNationalHealthand
Nutrition Examination Survey 1999–2000 and 2003–2004.
RESULTS — In adolescents, increased serum perﬂuorononanoic acid (PFNA) concentrations
were associated with hyperglycemia (odds ratio [OR] 3.16 [95% CI 1.39–7.16], P  0.05).
Increased serum PFNA concentrations also have favorable associations with serum HDL choles-
terol (0.67 [0.45–0.99], P  0.05). Overall, increased serum PFNA concentrations were in-
verselycorrelatedwiththeprevalenceofthemetabolicsyndrome(0.37[0.21–0.64],P0.005).
In adults, increased serum perﬂuorooctanoic acid concentrations were signiﬁcantly associated
with increased -cell function ( coefﬁcient 0.07  0.03, P  0.05). Increased serum perﬂuo-
rooctane sulfate (PFOS) concentrations were associated with increased blood insulin (0.14 
0.05, P  0.01), homeostasis model assessment of insulin resistance (0.14  0.05, P  0.01),
and -cell function (0.15  0.05, P  0.01). Serum PFOS concentrations were also unfavorably
correlated with serum HDL cholesterol (OR 1.61 [95% CI 1.15–2.26], P  0.05).
CONCLUSIONS — SerumPFCswereassociatedwithglucosehomeostasisandindicatorsof
metabolic syndrome. Further clinical and animal studies are warranted to clarify putative causal
relationships.
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T
he perﬂuoroalkyl chemicals (PFCs)
are a family of perﬂuorinated chem-
icals that consist of a carbon back-
bone typically 4–14 carbons in length
andachargedfunctionalmoiety(1).PFCs
have been used extensively since the
1950s in commercial applications, such
as inclusion as a component in surfac-
tants, lubricants, paper and textile coat-
ings, polishes, food packaging, and ﬁre-
retardant foams (2). Some of these PFCs,
including the most widely known exam-
ples, perﬂuorooctanoic acid (PFOA) and
perﬂuorooctane sulfate (PFOS), persist in
humans and the environment and have
been detected worldwide in wildlife (2).
The routes of human exposure to PFCs
are currently being investigated. Possible
exposure pathways that are being exam-
ined include drinking water, dust in
homes, and food or migration from food
packaging and cookware. Animal studies
have shown that these compounds are
well absorbed orally but are poorly elim-
inated; they are not metabolized and
undergo extensive uptake from enterohe-
patic circulation and are distributed
mainlytotheserum,kidney,andliver(1).
Although some PFCs have been voluntar-
ilyremovedfromthemarketbymanufac-
turers, PFOA and PFOS and their
derivatives are still produced commer-
cially, and the potential risk to humans
continues to be evaluated.
In animal studies, exposure to PFOS
and PFOA is associated with adverse
health effects, including carcinogenicity
(3,4), hepatotoxicity (4,5), and develop-
mental and reproductive toxicity (4). For
humans, PFC exposure has been shown
to be associated with certain types of can-
cers (6). Maternal exposure to PFOS and
PFOA also has been linked to low birth
weight (7).
The causal biochemical mechanisms
leading to the adverse health outcomes
after exposure to PFCs are largely un-
known. However, recent studies using
advanced technologies in genomics and
bioinformatics have shown that several
categories of genes are commonly altered
by some PFCs including those for peroxi-
some proliferation, fatty acid metabolism,
lipid transport, cholesterol synthesis, pro-
teosome activation and proteolysis, cell
communication, and inﬂammation (1).
The agonistic properties of PFCs on per-
oxisome proliferator-activated recep-
tors- [PPAR-] are well supported and
are thought to be a major mechanism
leading to PFC-mediated liver damage
(8,9). Because activation of PPAR- can
decrease serum triglycerides, normalize
LDL cholesterol, and increase HDL cho-
lesterol,wehypothesizedthatPFCsmight
have favorable effects on lipid homeosta-
sis and may also be associated with re-
duced insulin resistance, an improved
serum lipid proﬁle, and lower prevalence
of the metabolic syndrome. The goal of
the present study was to test this hypoth-
esis by examining data from the National
HealthandNutritionExaminationSurvey
(NHANES) collected from 1999–2000
and 2003–2004.
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METHODS— Data were from
NHANES 1999–2000 and 2003–2004.
The NHANES is a population-based sur-
veydesignedtocollectinformationonthe
health and nutrition of the U.S. house-
holdpopulationandtoobtainarepresen-
tative sample of the noninstitutionalized
civilian U.S. population. The survey data
arereleasedevery2years.Detailedsurvey
operations manuals, consent documents,
and brochures of the NHANES 1999–
2000 and 2003–2004 are available on the
NHANES Web site (10).
We limited our analyses to the 3,685
participants at least 12 years of age who
had a blood test for PFCs. Among these
subjects, only 1,788 subjects had a morn-
ing examination and had fasting plasma
glucose, insulin, and triglyceride data
available. Of these 1,788 participants, we
includedthe1,443subjectswithoutmiss-
ing data for further analyses.
Anthropometric and biochemical
data
According to the statements on the
NHANES Web site, data were collected at
all study sites by trained personnel fol-
lowing standardized procedures. Socio-
demographic information such as age,
sex, race/ethnicity, education level, and
household income was collected during
the household interview. Alcohol intake
was determined by the questionnaire (“in
any one year, have you had at least 12
drinks of any type of alcohol beverage?”)
and was dichotomized. For adolescents,
because there were too many missing
data, alcohol intake was not entered for
analysis. Smoking status was categorized
as active smoker, former/passive smoker,
andnonsmokerbythesmokingquestion-
naire and serum cotinine levels as de-
scribed previously (11). Laboratory
measurements were performed in a mo-
bile examination center. Weight and
height were measured using standard
methods and digitally recorded. Three
andsometimesfourbloodpressuredeter-
minations were collected by a physician
using a mercury sphygmomanometer.
Blood pressure was measured in the right
arm unless otherwise speciﬁed. Averaged
systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were ob-
tained. Blood specimens were processed
locally and then stored and shipped to
central laboratories for analysis. Levels of
serum total cholesterol and triglycerides
were measured enzymatically. Levels of
HDLcholesterolweremeasuredafterpre-
cipitation of other lipoproteins on a Hitachi
model704analyzer(RocheDiagnostics,In-
dianapolis, IN). Serum C-reactive protein
(CRP) levels were measured by latex-
enhanced nephelometry. Plasma insulin
was determined by an immunoenzymo-
metric assay. Insulin resistance status (ho-
meostasis model assessment of insulin
resistance [HOMA-IR]) and -cell function
wereestimatedbytheupdatedhomeostasis
model assessment (HOMA2) (12).
Deﬁnition of metabolic syndrome
For subjects 18 years old, presence of
the metabolic syndrome was calculated
by sex as deﬁned by the National Choles-
terolEducationProgramAdultTreatment
PanelIII(13)guidelineofpresentingwith
at least three of the following qualiﬁca-
tions: waist measurement 88 cm for
women and 102 cm for men; serum
triglycerides 1.69 mmol/l; serum HDL
cholesterol 1.03 mmol/l in men and
1.29 mmol/l in women; SBP 130
mmHg or DBP 85 mmHg or a self-
report of taking antihypertensive medica-
tions; and fasting glucose 6.10 mmol/l
or a self-report of taking antihyperglyce-
mic medications. To deﬁne the metabolic
syndrome among the young participants
aged between 12 and 17 years, we used a
previously proposed modiﬁcation of the
deﬁnition proposed in the National Cho-
lesterol Education Program Adult Treat-
ment Panel III. The participants had to
meet three of the following ﬁve criteria:
serum concentration of triglycerides
1.24 mmol/l; HDL cholesterol 1.04
mmol/l; waist circumference more than
or equal to the sex-speciﬁc 90th percen-
Table 1—Basic demography and serum concentrations of PFCs of the sample subjects
Unweighted no.
adolescent/adult
Adolescents (12
years, 20 years) Adults (20 years)
Age (years) 474/969 15.5  0.2 46.2  0.8
Sex (%)
Male 266/476 56.6  3.1 50.2  1.7
Female 208/493 43.4  3.1 49.8  1.7
Race (%)
Mexican American 182/273 11.7  2.5 8.7  1.7
Non-Hispanic white 123/510 71.7  3.5 80.8  2.5
Non-Hispanic black 169/186 16.6  2.6 10.5  1.7
Smoking (%)
Active smoker 66/197 19.1  2.1 25.3  2.5
Former/passive smoker 246/144 49.6  3.6 14.5  1.4
Nonsmoker 162/628 31.4  3.8 60.2  2.5
Alcohol drinking status (%)
12 drinks last year —/659 N/A 73.3  2.3
12 drinks last year —/310 N/A 26.7  2.3
Annual household income (%)
$25,000 186/352 27.3  3.1 25.2  2.4
$25,000–55,000 163/320 33.8  3.6 33.4  2.7
$55,000 125/297 38.9  3.9 41.4  2.2
Metabolic syndrome (%) 38/382 8.6  2.1 36.2  2.0
Waist (%) 124/786 26.4  2.7 81.2  1.8
Glucose (%) 35/212 7.3  2.1 15.7  1.5
HDL cholesterol (%) 96/313 23.8  3.1 32.6  2.3
Triglyceride (%) 86/364 21.8  2.8 34.6  2.2
Blood pressure (%) 49/470 8.3  1.6 42.0  2.2
Diabetes medication 0/79 0 4.8  0.7
Hypertension medication 0/245 0 19.5  1.5
Hyperlipidemia medication 0/118 0 9.7  1.0
Log CRP (mg/dl) 474/969 2.94  0.07 1.54  0.05
Log insulin (pmol/l) 474/969 4.05  0.04 3.99  0.04
Log PFHS (ng/ml) 474/969 0.95  0.10 0.60  0.04
Log PFNA (ng/ml) 474/969 0.35  0.07 0.21  0.07
Log PFOA (ng/ml) 474/969 1.51  0.05 1.48  0.04
Log PFOS (ng/ml) 474/969 3.11  0.05 3.19  0.04
Data are means  SEM unless indicated otherwise. N/A, no assessment.
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mmol/l or a self-report of taking antihy-
perglycemicmedications(15),andSBPor
DBP more than or equal to the age-,
height-, and sex-speciﬁc 90th percentile
or a self-report of taking antihypertensive
medications (16).
Assessment of serum PFCs
As part of NHANES, serum samples of
PFOA, PFOS, perﬂuorohexane sulfonic
acid (PFHS), and perﬂuorononanoic acid
(PFNA) were collected for analysis. The
analytical method has been described in
detail (17). In brief, without protein pre-
cipitation, only dilution with 0.1 M for-
mic acid, 1 aliquot of 100 l serum was
injected into a commercial column switch-
ingsystemallowingforconcentrationofthe
analytes on a C18 solid-phase extraction
column. This column was placed automat-
ically in front of a C8 analytical high-
performance liquid chromatography
column for chromatographic separation
of the analytes. Detection and quantiﬁca-
tionweredoneusingnegative-ionTurbo-
IonSpray ionization tandem mass
spectrometry. Isotope-labeled internal
standards were used for quantiﬁcation.
Statistics
Data are expressed as means  SEM. Par-
ticipants were divided into adolescents
(12–20yearsofage)andadult(20years
of age) groups for analysis. The strength
of the associations between concentra-
tions of various serum PFCs and blood
glucose,insulin,andHOMA-IRlevelswas
tested using multiple linear regression
models. Logistic regression analyses were
conducted to examine the odds ratios
(ORs) of metabolic syndrome (yes or no
for having at least three components of
metabolic syndrome) and its components
(yes/no for that component) associated
with a 1 unit increase in log PFCs. Log
transformation was performed for variables
with signiﬁcant deviation from normal dis-
tribution before further analyses. For linear
regression, we used an extended model ap-
proachforcovariateadjustment:model1
age, sex, and race; model 2  model 1 	
health behaviors (smoking status, alcohol
intake, and household income); and
model 3  model 2 	 measurement data
(waist measurement, CRP, and insulin/
glucose/HOMA) 	 current medications
(antihypertensive, antihyperglycemic,
and antihyperlipidemic agents). For lo-
gistic regression, the models for adjust-
mentwereasfollows:model4age,sex,
race,healthbehaviors(smokingstatus,al-
cohol intake and household income),
measurement data (CRP and HOMA/
insulin), and current medications (anti-
hypertensive, antihyperglycemic, and
antihyperlipidemic agents) and model
5  model 4 	 other components of the
metabolic syndrome. P  0.05 was con-
sidered statistically signiﬁcant. To avoid
“model-dependent association,” the asso-
ciation was considered signiﬁcant only
when it remained statistically signiﬁcant
in all models. Sampling weights that ac-
count for unequal probabilities of selec-
tion, oversampling, and nonresponse
were applied for all analyses using the
Complex Sample Survey module of SPSS
(version13.0forWindowsXP;SPSS,Chi-
cago, IL).
RESULTS— The basic demographic
characteristics of the participants are
summarizedinTable1.Thestudysample
consisted of 474 adolescents (aged be-
tween 12 and 20 years) and 969 adults
(age 20 years). The serum PFHS levels
were signiﬁcantly higher in adolescents
than in adults (log PFHS ng/ml 0.95 
0.10 vs. 0.60  0.04, respectively, P 
0.001),whereastheserumPFNAconcen-
trations were lower in adolescents than in
adults(logPFNAng/ml0.350.07vs.
0.21  0.07, P  0.001). The serum
PFOA and PFOS concentrations were not
different between these two groups.
The associations between the serum
PFC levels and glucose homeostasis
markers are shown in Table 2. In adoles-
Table 2—Linear regression coefﬁcients with 1-unit increase in log PFCs in adolescents and
adults
 coefﬁcient
Log PFHS Log PFNA Log PFOA Log PFOS
Adolescent
Glucose
Model 1 0.02  0.03 0.04  0.04 0.04  0.05 0.03  0.06
Model 2 0.02  0.03 0.05  0.05 0.04  0.05 0.04  0.06
Model 3 0.01  0.03 0.07  0.04 0.03  0.05 0.03  0.06
Log insulin
Model 1 0.02  0.04 0.09  0.05 0.05  0.08 0.06  0.07
Model 2 0.03  0.04 0.10  0.05 0.07  0.09 0.07  0.07
Model 3 0.06  0.03 0.10  0.05* 0.08  0.07 0.15  0.08
Log HOMA-IR
Model 1 0.02  0.04 0.09  0.05 0.04  0.08 0.05  0.07
Model 2 0.02  0.05 0.09  0.05 0.06  0.09 0.07  0.07
Model 3 0.05  0.03 0.08  0.04 0.08  0.05 0.15  0.07
Log -cell function
Model 1 0.03  0.04 0.12  0.07 0.06  0.10 0.06  0.08
Model 2 0.03  0.04 0.12  0.06 0.08  0.10 0.08  0.08
Model 3 0.05  0.03 0.12  0.06* 0.08  0.08 0.13  0.09
Adult
Glucose
Model 1 0.07  0.09 0.05  0.04 0.11  0.10 0.03  0.08
Model 2 0.05  0.09 0.02  0.05 0.11  0.11 0.23  0.09
Model 3 0.02  0.06 0.00  0.04 0.09  0.08 0.03  0.07
Log insulin
Model 1 0.04  0.05 0.06  0.04 0.08  0.04 0.13  0.05*
Model 2 0.04  0.05 0.05  0.04 0.08  0.04 0.13  0.05*
Model 3 0.01  0.03 0.04  0.03 0.07  0.03* 0.14  0.05†
Log HOMA-IR
Model 1 0.05  0.05 0.06  0.04 0.06  0.05 0.12  0.05*
Model 2 0.04  0.05 0.06  0.05 0.07  0.05 0.12  0.05*
Model 3 0.00  0.04 0.04  0.04 0.06  0.04 0.14  0.05†
Log -cell function
Model 1 0.02  0.04 0.05  0.03 0.09  0.04* 0.14  0.06*
Model 2 0.02  0.04 0.05  0.04 0.09  0.04* 0.14  0.06*
Model 3 0.01  0.03 0.04  0.03 0.07  0.03* 0.15  0.05†
Data are means  SEM. *P  0.05; †P  0.01. Model 1 adjusted for age, sex, race; model 2 adjusted for
model 1 	 health behaviors (smoking status, alcohol intake, and household income); model 3 adjusted for
model 2 	 measurement data (waist circumference, CRP, and insulin/glucose/HOMA) 	 medications.
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tions were associated with decreased
blood insulin ( coefﬁcient 0.10 
0.05, P  0.05) and -cell function
(0.12  0.06, P  0.05) with border-
line signiﬁcance (P  0.05–0.09 in all
models and 0.05 in the ﬁnal model).
Other PFCs were not associated with the
serum markers for glucose homeostasis.
In adults, increased serum PFOA concen-
trationsweresigniﬁcantlyassociatedwith
increased -cell function ( coefﬁcient
0.07  0.03, P  0.05). Increased serum
PFOSconcentrationswerealsoassociated
with increased blood insulin (0.14 
0.05,P0.01),HOMA-IR(0.140.05,
P  0.01), and -cell function (0.15 
0.05, P  0.01).
The associations between the serum
PFCs and the metabolic syndrome/
metabolic syndrome components are
summarized in Table 3. In adolescents,
increased serum PFNA concentrations
were associated with a lower prevalence
of the metabolic syndrome (OR 0.37
[95% CI 0.21–0.64], P  0.005) and
HDLcholesterolbelowthemetabolicsyn-
drome criteria (0.67 [0.45–0.99], P 
0.05). Increased serum PFNA concentra-
tions were also correlated with a higher
prevalence of blood glucose above the
metabolic syndrome deﬁnition (3.16
[1.39–7.16], P  0.05). We also found
that the serum PFOS (0.37 [0.16–0.82],
P  0.05) concentrations were inversely
correlated with a lower prevalence of
waist circumference than the metabolic
syndrome deﬁnition. In adult subjects,
among all the PFCs and metabolic syn-
drome components, only serum PFOS
concentrations were associated with a
higher prevalence of HDL cholesterol be-
low the metabolic syndrome deﬁnition
(1.61 [1.15–2.26], P  0.05).
CONCLUSIONS — To our knowl-
edge,thisreportistheﬁrsttosystemically
analyze the link among serum PFC con-
centration, glucose homeostasis, and the
metabolicsyndrome/metabolicsyndrome
componentsinanationallyrepresentative
sample. In this study, we showed that
PFCs were differentially associated with
glucose homeostasis in adolescents and
adults. We should consider carefully the
extrapolation and interpretation of data
between laboratory animal studies and
the corresponding biological effects (at
high parts per million range) compared
with general human populations (at low
partsperbillionrange).Wefoundthatthe
concentrations reported for PFCs in the
occupational studies have been 2 and 3
orders of magnitude higher than those
measured in the general population. Al-
though there were several studies re-
garding maternal exposure and child
Table 3—ORs of metabolic syndrome and its components associated with 1-unit increase in log PFCs in adolescents and adults
Log PFHS Log PFNA Log PFOA Log PFOS
Adolescent
Metabolic syndrome
Model 4 0.56 (0.22–1.45) 0.37 (0.21–0.64)‡ 0.79 (0.30–2.12) 0.49 (0.18–1.30)
Metabolic syndrome waist
Model 4 0.72 (0.48–1.09) 0.99 (0.59–1.63) 0.61 (0.32–1.13) 0.41 (0.21–0.83)*
Model 5 0.64 (0.45–0.91)* 1.09 (0.61–1.95) 0.58 (0.34–1.00)* 0.37 (0.16–0.82)*
Metabolic syndrome glucose
Model 4 1.10 (0.46–2.62) 3.15 (1.39–7.12)* 0.46 (0.25–0.85)* 0.58 (0.31–1.10)
Model 5 0.98 (0.44–2.17) 3.16 (1.39–7.16)* 0.55 (0.24–1.25) 0.58 (0.28–1.14)
Metabolic syndrome HDL
cholesterol
Model 4 0.93 (0.58–1.47) 0.59 (0.42–0.83)† 1.20 (0.60–2.39) 0.89 (0.51–1.55)
Model 5 0.93 (0.60–1.43) 0.67 (0.45–0.99)* 1.50 (0.67–3.36) 1.38 (0.61–3.14)
Metabolic syndrome triglycerides
Model 4 1.07 (0.76–1.52) 0.68 (0.40–1.15) 1.64 (0.72–3.73) 0.95 (0.50–1.80)
Model 5 1.08 (0.83–1.40) 0.71 (0.37–1.34) 1.15 (0.54–2.47) 0.78 (0.41–1.49)
Adult
Metabolic syndrome
Model 4 0.93 (0.73–1.19) 0.92 (0.69–1.24) 1.07 (0.73–1.57) 1.25 (0.86–1.82)
Metabolic syndrome waist
Model 4 0.73 (0.53–0.99)* 1.25 (0.88–1.74) 0.95 (0.63–1.45) 0.89 (0.59–1.34)
Model 5 0.80 (0.58–1.10) 1.34 (0.93–1.92) 0.97 (0.65–1.46) 0.91 (0.59–1.41)
Metabolic syndrome glucose
Model 4 0.79 (0.53–1.16) 0.81 (0.62–1.07) 0.89 (0.63–1.26) 0.83 (0.64–1.08)
Model 5 0.76 (0.54–1.07) 0.86 (0.66–1.12) 0.87 (0.61–1.26) 0.81 (0.62–1.05)
Metabolic syndrome HDL
cholesterol
Model 4 0.90 (0.69–1.18) 0.80 (0.65–0.99)* 1.14 (0.84–1.55) 1.47 (1.07–2.00)*
Model 5 1.00 (0.73–1.37) 0.81 (0.65–1.00) 1.22 (0.86–1.71) 1.61 (1.15–2.26)*
Metabolic syndrome triglycerides
Model 4 0.80 (0.64–0.99)* 0.98 (0.82–1.16) 0.91 (0.69–1.20) 0.97 (0.73–1.27)
Model 5 0.78 (0.60–1.02) 0.99 (0.81–1.19) 0.86 (0.65–1.13) 0.86 (0.65–1.16)
Data are OR (95% CI). *P  0.05; †P  0.01; ‡P  0.005. Model 4 adjusted for age, sex, race, health behaviors (smoking status, alcohol intake, and household
income), measurement data (CRP and HOMA/insulin) and medications. Model 5 adjusted for model 4 	 other components of the metabolic syndrome.
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health outcome, the relationship of se-
rum PFC levels to medical diseases and
laboratory abnormality in a nationally
representative survey has never been
explored.Ourresultsmightsuggestthat
low-dose PFC exposure may have ef-
fects on glucose metabolism in the gen-
eral population.
Our analysis showed that the serum
PFOA and PFOS concentrations were not
different between adolescents and adults.
Unlike other lipophilic persistent pollut-
ants that display increasing serum con-
centrations as individuals age, the lack of
this general trend in PFOS and PFOA
could be explained by intrauterine trans-
fer, exposure early in life with ongoing
exposures being much higher than earlier
historical exposures, or a combination of
these factors (18). In contrast, the mean
concentrations of PFHS were higher for
adolescents than for adults, as reported
previously (2,19). The higher concentra-
tions of PHFS in children and adolescents
couldberelatedtotheirincreasedcontact
with carpeted ﬂoors containing PFHS,
which is used for speciﬁc postmarket car-
pet treatment applications (2,19).
We showed that in adolescents, in-
creasedserumPFNAconcentrationswere
associated with decreased blood insulin,
impaired -cell function (borderline sig-
niﬁcance), and clinical hyperglycemia.
Ontheotherhand,wefoundthatincreased
serum PFNA had a favorable correlation
with serum HDL cholesterol. Overall, in-
creased serum PFNA concentrations were
inversely associated with the prevalence of
metabolic syndrome in adolescents. In
adults, serum PFOS concentrations were
independently associated with increases in
both blood insulin and insulin resistance
status (HOMA-IR). Interestingly, both se-
rum PFOA and PFOS were also positively
correlatedwith-cellfunction.Thebalance
between increased insulin resistance and
-cellfunctionhasaneutraleffectonblood
glucose. Increased PFOS also showed an
unfavorable association with serum HDL
cholesterol in adults. Overall, the PFCs in
the present study had neutral effects on the
prevalence of the metabolic syndrome in
adults.
There has been a great deal of
progress in the last few years in under-
standing the toxicology and distribution
of PFCs in the environment, in wildlife,
and in humans. However, there is a pau-
city of information pertaining to many
speciﬁc PFCs (1). Thus far, there are no
published reports of either in vitro or in
vivo data pertaining to effects of PFCs on
glucose homeostasis. The underlying
mechanisms of this linkage are unknown
and might partially be related to peroxi-
some activation. The liver toxicity of
PFOS and PFOA has been linked to their
PPAR- agonist property (8,9). PFNA
also has been shown to be a strong perox-
isomal -oxidation inducer in animals
(20,21).Fibrates,amphipathiccarboxylic
acids that activate PPAR-, can decrease
triglycerides, normalize the LDL choles-
terol proﬁle, and increase HDL choles-
terol (22). However, our results are not
entirely consistent with previous animal
ﬁndings, suggesting alternative or even
multiple pathways in association among
PFCs, glucose, and lipid metabolism. For
example,Luebkeretal.(23)havedemon-
strated that both PFOS and PFOA can in-
terfere with the binding afﬁnity of liver
fatty acid–binding protein in rodents. In-
terestingly, they also found that among
thePFCstested,PFOSexhibitedthehigh-
est level of inhibition of liver fatty acid–
binding protein, which might partially
explain the unfavorable association be-
tween increased serum PFOS and HDL
cholesterol.
Our studyhasseverallimitations.First,
the cross-sectional design does not permit
any causal inference. Second, because of
missing data, drinking status was not in-
cluded in our analyses of adolescents.
In summary, we present the ﬁrst re-
port of a relationship between serum
PFCs, glucose homeostasis, and metabolic
syndrome. Because PFCs have been widely
used worldwide in a variety of consumer
products, further longitudinal clinical and
in vitro studies are urgently needed to
elucidatetheputativecasualrelationships
between PFCs and metabolism.
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